Gangrene future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
A novel [[gene therapeutic approach]] is currently conducted to promote [[reperfusion]] and [[angiogenesis]] of [[ischemic tissues]], which can help in [[limb salvage]]. Ongoing study on this approach is conducted on mice and it involves the [[intramuscular injection]] of [[adeno-associated virus]]/ ([[AAV]]) [[vector]], and [[E-selectin]]. | |||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Revision as of 02:17, 10 April 2022
|
Gangrene Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Gangrene future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Gangrene future or investigational therapies |
|
Risk calculators and risk factors for Gangrene future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.
Overview
A novel gene therapeutic approach is currently conducted to promote reperfusion and angiogenesis of ischemic tissues, which can help in limb salvage. Ongoing study on this approach is conducted on mice and it involves the intramuscular injection of adeno-associated virus/ (AAV) vector, and E-selectin.